There were 969 press releases posted in the last 24 hours and 190,445 in the last 365 days.

Antidepressant Drugs Market is Generating Revenue of $15.98 Billion by 2023, at CAGR 2.1% Growth Rate

Antidepressant Drugs

Increase in the number of patients suffering from depression, stress with emergence of novel drugs with fewer side-effects to boost the growth of the market

The increase in awareness in regards with the disease state and importance of clinical needs, rise in prevalence of depression are the major driving factors to boost the market growth.”
— Mangesh Panhale

The global antidepressant drugs market accounted for $14.11 billion in 2017 and is expected to reach $15.98 billion by 2023, registering a CAGR of 2.1% during the forecast period.

Increased global disease burden of depression, rise in geriatric population, and emergence of innovative techniques for the development of drugs with fewer side-effects drive the growth of the market. However, poor efficacy and safety profiles of drugs, inclination toward non-pharmacological therapies, and increase in the number of patent expiration of antidepressants hamper the market growth. On the contrary, increase in awareness regarding the disease state and rise in number of patients suffering from stress are expected to create lucrative opportunities for the market players in future.

To Get the Sample Copy of Report Visit @

Obsessive-compulsive disorder segment to portray fastest demand through 2023

The obsessive-compulsive disorder segment is expected to register the fastest CAGR of 2.9% during the forecast period, owing to changing lifestyle and need for better quality of life. However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels. The other segments analyzed in the report include generalized anxiety disorder, panic disorder, and others.

Selective serotonin reuptake inhibitors segment to lead the market by 2023

Selective serotonin reuptake inhibitors segment is projected to manifest the fastest CAGR of 2.7% during the forecast period, as these are highly effective in treat depression and anxiety due to their minimal side-effects. The other antidepressant products analyzed in the report are tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, and others.

For Purchase Enquiry @

North America to retain the largest market share through 2023

North America accounted for the largest share in the market, contributing more than half of the total revenue, owing to increase in incidence of disorders such as stress, suicidal feelings, serious psychological disorders, and anxiety among the adult population in the region. However, Asia-Pacific region is expected to portray the fastest CAGR of 4.0% during the study period, owing to the increase in marketing approval for new medicines in the region and presence of large pool of geriatric population. The other regions analyzed in the report include Europe and Latin America, Middle East and Africa (LAMEA).

The Major Key Players Are:

Alkermes Plc, Allergan Plc, Bristol Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd.

The Other Prominent Players Are:

Opko Health, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Abbott Laboratories, Novartis, Forest Laboratories, and AstraZeneca.

Access Full Report @

Key Findings of the Antidepressant Drugs Market:

• Obsessive compulsive disorder is projected to grow at the highest rate during the analysis period.
• North America dominated global antidepressant drugs market in 2016, and is projected to continue its dominance in future.
• China is expected to grow highest in Asia-Pacific during the forecast period.
• Major depressive disorder is the largest contributor among the depressive disorder segments in 2016.
• Selective serotonin reuptake inhibitors segment generated the highest revenue, and is expected to continue its dominance in future.

Similar Reports:

Top 10 Cancer Drugs Market Analysis and Industry Forecast, 2027

Ophthalmic Drugs Market Analysis and Industry Forecast, 2027

Anticoagulants Market Analysis and Industry Forecast, 2027

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media: